FLT3 and acute myeloid leukemia: Combining FT538 iPSC‐NK cells with the FLT3 inhibitor gilteritinib resulted in a higher rate of AML cell apoptosis in the FLT3‐mutant cell lines Molm‐13 and MV4‐11 than treating with the FT538 iPSC‐NKs alone.